Effects of Tumor Necrosis Factor-alpha Inhibitors on the Incidence of Tuberculosis

키워드

참고문헌 (40)

1. Bradley JR, "TNF-mediated inflammatory disease", J Pathol, 214, pp.149~160 (2008)
2. Firestein GS, "Common mechanisms in immune-mediated inflammatory disease", J Rheumatol Suppl, 73, pp.8~13 (2005)
3. Kuek A, "Immunemediated inflammatory diseases(IMIDs)and biologic therapy : a medical revolution", Postgrad Med J, 83, pp.251~260 (2007)
4. Blandizzi C, "The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases", Int J Immunopathol Pharmacol, 27(Suppl), pp.1~10 (2014)
5. Burmester GR, "Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice : the research in active rheumatoid arthritis(ReAct)trial", Ann Rheum Dis, 66, pp.732~739 (2007)
6. Sampaio-Barros PD, "Adverse effects of TNF inhibitors in SpA: are they different from RA?", Best Pract Res Clin Rheumatol, 28, pp.747~763 (2014)
7. Askling J, "Risk and case characteristics of tuberculosis in rheumatoidarthritis associated with tumor necrosis factor antagonists inSweden", Arthritis Rheum, 52, pp.1986~1992 (2005)
8. Dixon WG, "Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British society for rheumatology biologics register", Arthritis Rheum, 54, pp.2368~2376 (2006)
9. Ai JW, "The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-a antagonist : a metaanalysis of both randomized controlled trials and registry", cohort studies, 2015, pp.42(12), 2229~2237
10. Bonovas S, "Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease:a systematic review and network meta-analysis", Clin Gastroenterol Hepatol, 14(10), pp.1385~1397 (2016)
11. Capogrosso Sansone A, "Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases : a systematic review and meta-analysis", Drug Saf, 38(10), pp.869~888 (2015)
12. Ford AC, "Opportunistic infections with anti-tumor necrosis factor- α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials", Am J Gastroenterol, 108(8), pp.1268~1276 (2013)
13. Liao H, "Comparison of the risk of infections in different anti-TNF agents : a meta-analysis", Int J Rheum Dis, 20(2), pp.161~168 (2017)
14. Minozzi S, "Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis", Expert Opin Drug Saf, 15(suppl), pp.11~34 (2016)
15. Vicente Ruiz Garcia, "Certolizumab pegol (CDP870) for rheumatoid arthritis in adults", Cochrane Database of Systematic Reviews (2017), Wiley[DOI]
16. Jasvinder A Singh, "Golimumab for rheumatoid arthritis", Cochrane Database of Systematic Reviews (2010), Wiley[DOI]
17. Souto A, "Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib : a systematic review and meta-analysis of randomized controlled trials and long-term extension studies", Rheumatology, 53, pp.1872~1885 (2014)
18. Wang Q, "Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy:a meta-analysis", Exp Ther Med, 12(3), pp.1693~1704 (2016)
19. Xie X, "Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis", Zhong Nan Da Xue Xue Bao Yi Xue Ban, 38(7), pp.722~736 (2013)
20. Xu Z, "Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy : a meta-analysis of randomized controlled trials", Exp Ther Med, 14(4), pp.3491~3500 (2017)
21. Zheng Zhang, "Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials", BMJ Open, 7(3), pp.e012567~ (2017), BMJ[DOI]
22. Ke WM, "Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan", Int J Tuberc Lung Dis, 17(12), pp.1590~1595 (2017)
23. Wallis RS, "Reactivation of latent tuberculosis by TNF blockade : the role of interferon gamma", J Investig Dermatol Symp Proc, 12(1), pp.16~21 (2007)
24. Green S, "Cochrane handbook for systematic reviews of interventions (version 5.1.0)" (2011), The Cochrane Collaboration
25. Michelle Pollock, "What guidance is available for researchers conducting overviews of reviews of healthcare interventions? A scoping review and qualitative metasummary", Systematic Reviews, 5(1) (2016), Springer Nature[DOI]
26. "Chapter 9: Analysing data and undertaking meta-analyses, Cochrane handbook for systematic reviews of interventions version 5.0.0" (2008)[URL]
27. Fusar-Poli P, "Ten simple rules for conducting umbrella reviews", Evid Based Ment Health, 21(3), pp.95~100 (2018)
28. Wang Z, "Converting odds ratio to relative risk in cohort studies with partial data information", J Stat Soft, 55(5), pp.1~11 (2013)
29. Becker LA, "Cochrane handbook for systematic reviews of interventions (version 5.1.0)" (2011), The Cochrane Collaboration
30. Solovic I, "The risk of tuberculosis related to tumour necrosis factor antagonist therapies : a TBNET consensus statement", Eur Respir J, 36, pp.1185~1206 (2010)
31. Wallis RS, "Tumour necrosis factor antagonists: structure, function, and tuberculosis risks", Lancet Infect Dis, 8(10), pp.601~611 (2008)
32. Scallon B, "Binding and functional comparisons of two types of tumor necrosis factor antagonists", J Pharmacol Exp Ther, 301(2), pp.418~426 (2002)
33. Scallon BJ, "Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNFalpha and activates immune effector functions", Cytokine, 7(3), pp.251~259 (1995)
34. Banner DW, "Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex : implications for TNF receptor activation", Cell, 73(3), pp.431~445 (1993)
35. Bonovas S, "Safety of biological therapies in ulcerative colitis: an umbrella review of meta-analyses", Best Pract Res Clin Gastroenterol, 32-33, pp.43~47 (2018)
36. "Micromedex Solutions"[URL]
37. "Micromedex Solutions"[URL]
38. "Micromedex Solutions"[URL]
39. "Golimumab. Micromedex Solutions"[URL]
40. "Micromedex Solutions"[URL]